leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
Published 2 years ago • 736 plays • Length 1:35:31Download video MP4
Download video MP3
Similar videos
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
1:20:02
her2-low expression in breast cancer: opportunities for expanding treatment benefit to more patients
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
1:16:18
serds at the inflection point in pretreated er /her2- breast cancer: novel er-targeting therapies
-
1:30:06
moving toward expanded precision treatment of her2- or her3-driven breast, gi, lung & other cancers
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
32:54
raising the bar in her2-positive breast cancer
-
51:24
her2 and her3 alterations as therapeutic targets of increasing significance in solid tumors
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
1:18:52
her2-positive gastrointestinal cancers: new evidence and practical guidance with targeted agents
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
55:30
breaking down barriers to treatment adherence and persistence in hr /her2- early breast cancer
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
2:31
results of the aphinity trial in her2-positive breast cancer